ImmunityBio, Inc.
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG007T9DYW9
IBRX
ImmunityBio, Inc.
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Biotechnology
NAME
ImmunityBio, Inc.
ISIN
US45256X1037
TICKER
IBRX
MIC
XNAS
REUTERS
IBRX.OQ
BLOOMBERG
IBRX US
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Di., 15.04.2025
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive NMIBC in papillary disease and an EAP for ANKTIVA® (nogapendekin alfa inbakicept-pmln) for the treatment of lymphopenia.
Supplemental Biologics License Application (sBLA):
...
ImmunityBio
Di., 08.04.2025
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with a single institutional investor, providing for the issuance ...
ImmunityBio
Mo., 07.04.2025
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced details about its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company’s business operations, U.S. and global regulatory advances of its clinical-stage products, with fireside chats h...
ImmunityBio
Mi., 26.03.2025
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, invites current and prospective investors to its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company’s business operations and recent R&D advancements. Key timelines for catalysts of product can...
ImmunityBio
Do., 13.03.2025
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty services, is one of the first providers to participate in ImmunityBio’s Expanded Access Program (EAP) for recombinant Bacillus Calmette-Guérin (rBCG) to address...
ImmunityBio
Mo., 03.03.2025
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028) in January 2025, as well as its financial results for the fourth-quarter and full year ended December 31, 2024.
With the issuance of the permanent J-code in January 2025, ImmunityBio ha...
ImmunityBio
Fr., 28.02.2025
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for ANKTIVA® and CAR-NK (PD-L1 t-haNK) for the reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Multiply ...
ImmunityBio
Mi., 19.02.2025
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) that will bring a vital alternative source of BCG, a standard-of-care medicine in bladder cancer, to patients in the U.S.
Supply shortages of TICE® BCG in the U.S. have beco...
ImmunityBio
Do., 13.02.2025
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunity therapy company, today announced the Medicines and Healthcare products Regulatory Agency (MHRA) has validated and accepted the marketing authorization application for ANKTIVA. The MHRA will now begin assessing the marketing authorization application (MAA) for ANKTIVA® (nogapendekin alfa inbakice...
ImmunityBio
Mi., 29.01.2025
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne Medicines, Ltd.), a global oncology company, to conduct a confirmatory randomized Phase 3 clinical trial (ResQ201A-NSCLC), combining BeiGene's tislelizumab, a PD-1 checkpoint inhibitor (CPI), and Immu...
ImmunityBio
Informationen zu Product Placements
SMART * AD
P R O D U C T S U G G E S T I O N S
